Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Testosterone therapy reshapes bodies of transgender men, study finds

NCT ID NCT07481942

Knowledge-focused Sponsor: Celia Bañuls Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how one year of testosterone therapy changes body composition in 70 transgender men. Researchers used bioelectrical impedance and muscle ultrasound to track muscle gain and fat redistribution. The goal is to find better ways to monitor these changes and understand differences between testosterone types.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
testosterone (gender-affirming hormone therapy)
What this could lead to
If successful, this could help doctors better monitor muscle and fat changes in transgender men on hormone therapy, improving personalized care.
What could go wrong
This is a small, completed observational study with 70 participants. Results may not apply to all transgender men, and the methods (BIVA, ultrasound) need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Jan 2017

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants were recruited from the Gender Identity Unit of the Department of Endocrinology and Nutrition at University Hospital Doctor Peset (Valencia, Spain). All individuals underwent psychological evaluation by an experienced sexologist, who confirmed gender dysphoria according to DSM-V criteria, and prior to inclusion had been approved for gender-affirming medical intervention.

Ages

14 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Transgender men with confirmed gender dysphoria according to DSM-V criteria by an experienced sexologist. * Testosterone-naïve status * ≥14 years * Absence of prior or planned mastectomy or genital surgery during the study period Exclusion Criteria: * Diagnosed eating disorders, severe illness, neuromuscular or malignant disease, cardiovascular disease, and/or diabetes mellitus * Conditions contraindicating bioelectrical impedance analysis (pregnancy, lactation, or pacemaker) * Started GAHT prior to inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Transgender are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Transgender

Contacts and locations

Locations

  • FISABIO

    Valencia, Valencia, 46020, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.